APAC Alzheimer’s Disease Drugs Market

APAC Alzheimer’s Disease Drugs Market Executive Summary

The APAC Alzheimer’s Disease Drugs market was valued at $3.24 Bn in 2022 and is estimated to expand at a Compound Annual Growth Rate (CAGR) of 9.69% from 2022 to 2030 and will reach $6.79 Bn in 2030. Alzheimer's disease is characterized by nerve cell degeneration throughout the brain. It impairs cognitive functions such as memory, language, thinking, and behavior. Sadness, memory loss, loss of inhibitions, and problems with thinking and reasoning are all prevalent Alzheimer's Disease symptoms. Medical examinations, blood tests, brain imaging, and mental status and neuropsychological testing are commonly used to make the diagnosis. Based on the findings, doctors prescribe various medications to alleviate symptoms. Medication for Alzheimer's disease affects the activity of neurotransmitters, which are chemicals that convey impulses between nerve cells in the brain.

Alzheimer’s in the Asia Pacific Region' aims to increase understanding and awareness of the social and economic impact of dementia in Asia Pacific countries. The number of dementia patients in the region is expected to rise from 23 Mn in 2015 to over 71 Mn by 2050.

Market Dynamics

Market Growth Drivers

The APAC region has a rapidly aging population, which is driving the prevalence of Alzheimer's disease. According to a report by the United Nations, the number of people aged 65 and above in the Asia-Pacific region is expected to reach 524 Mn by 2030. This growing elderly population is expected to drive the demand for Alzheimer's drugs in the region. There is increasing awareness about Alzheimer's disease and its early diagnosis and treatment in the APAC region. This is leading to a higher rate of diagnosis and treatment, which is driving the demand for Alzheimer's drugs. Several governments in the APAC region are taking initiatives to improve the healthcare infrastructure and increase awareness about Alzheimer's disease. For instance, in India, the government has launched the National Dementia Strategy to improve the diagnosis and treatment of dementia, including Alzheimer's disease.

Market Restraints

Alzheimer's drugs can be expensive, which is a major challenge in the APAC region where many patients may not have access to affordable healthcare or insurance. This can limit the market growth and restrict the adoption of Alzheimer's drugs in the region. While there is increasing awareness about Alzheimer's disease, there is still a significant lack of awareness and diagnosis in many parts of the APAC region. This can result in underdiagnosis and undertreatment of the disease, which can limit the market growth. Many parts of the APAC region have limited access to healthcare facilities, which can limit the diagnosis and treatment of Alzheimer's disease. This can restrict the market growth and limit the adoption of Alzheimer's drugs in the region.

Competitive Landscape

Key Players

• Biogen
• Daiichi Sankyo Company
• Eisai Co.
• Eli Lilly and Company
• H. Lundbeck A/S
• Johnson and Johnson
• H Lundbeck
• Novartis AG
• Pfizer
• Merck

Healthcare Policies and Regulatory Landscape

The APAC Alzheimer's Disease medicines market's regulatory landscape is complicated and heavily regulated. Regulatory organizations in many nations and areas have particular standards and regulations for the development, approval, and marketing of Alzheimer's disease medications. APACly Alzheimer's Disease International, on the other hand, is a non-profit international federation of Alzheimer's Disease and dementia organizations from around the world. ADI has more than 100 member organizations in over 90 countries. It is estimated that 50 million individuals worldwide are living with dementia, with roughly 10 million new cases diagnosed each year. The annual Total cost of dementia care is expected to be more than $1 trillion.

The organization is officially affiliated with the World Health Organization. ADI advocates for persons affected by Alzheimer's disease and other forms of dementia. The organization seeks to make dementia an APAC, regional, and local priority by empowering Alzheimer's Disease and dementia associations to campaign for dementia as a national priority, create awareness, and give care and support to individuals with dementia and their careers, as well as pressing governments for improved policies and supporting investment and innovation in dementia research.

Reimbursement Scenario

The reimbursement scenario for Alzheimer's drugs in the APAC region can vary significantly depending on the country and the specific drug in question. Here are some general trends:

In Japan, the national health insurance program covers the majority of prescription drugs, including Alzheimer's drugs. The Japanese government sets drug prices through negotiations with manufacturers, and these prices are generally lower than in other countries. The Japanese government also has a system for "conditional approval" of drugs, which allows patients to access new drugs before they are fully approved if there is sufficient evidence of their safety and efficacy. Whereas China has a complex healthcare system, and reimbursement policies for Alzheimer's drugs can vary by region. Generally, drugs must be approved by the China National Medical Products Administration (NMPA) before they can be reimbursed. The government sets prices for reimbursed drugs, and these prices are typically much lower than in other countries. In some cases, patients may have to pay out of pocket for drugs that are not covered by insurance.

Likewise, India has a mix of public and private healthcare systems, and reimbursement policies for Alzheimer's drugs can vary. The Indian government has a price control mechanism for essential drugs, which includes some Alzheimer's drugs. Private insurance companies may also cover the cost of Alzheimer's drugs, but coverage can vary depending on the policy.